We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca has halted a second Phase III trial studying zibotentan as monotherapy in patients with non-metastatic, castrate-resistant prostate cancer (CRPC) due to a lack of efficacy.